🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Poland
Clinical trial register · European Union · CTIS

Clinical Trials in Poland

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 21 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 587 Netherlands 524 Belgium 426 Czechia 327
All 28 states
39 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
2025-523142-28-00Chronic Obstructive Pulmonary Disease (COPD) Chronic Rhinos…
Bambusa Therapeutics Inc.
Respiratory Tract Diseases
Poland
16/02/2026
Phase I
A study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumatoid arthritis
2025-523409-13-00Moderate to Severe Rheumatoid Arthritis
Lifordi Immunotherapeutics Inc.
Immune System Diseases
Poland
30/01/2026
Phase I
A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911
2025-523355-59-00Immune Thrombocytopenia, Hematopoietic Syndrome of Acute Ra…
Qilu Pharmaceutical Co. Ltd.
Hemic and Lymphatic Diseases
Poland
26/01/2026
Phase I
Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)
2025-523010-89-00Pulmonary arterial hypertension
35Pharma Inc.
Cardiovascular Diseases
Hungary, Spain, Poland, Germany, Czechia
23/12/2025
Phase I
A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants with Parkinson’s Disease and Apathy
2025-523612-37-00Parkinson's Disease and Apathy
Integrative Research Laboratories Sweden AB
Nervous System Diseases
Bulgaria, Poland, Spain, Germany
12/12/2025
Phase I
First-in-Human Study of RO7812653
2025-522101-37-00Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitiv…
F. Hoffmann-La Roche AG
Nervous System Diseases
Sweden, Poland, Spain, Netherlands
02/12/2025
Phase I
A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)
2024-518780-36-00Systemic Lupus Erythematosus
Cullinan Therapeutics Inc.
Musculoskeletal Diseases
Bulgaria, Romania, France, Germany, Spain, Poland
25/11/2025
Phase I
BBT001 in Healthy Volunteers and in Adult Patients with Atopic Dermatitis
2025-522918-23-00Atopic Dermatitis
Bambusa Therapeutics Inc.
Skin and Connective Tissue Diseases
Poland
21/11/2025
Phase I
Comparison of Prefilled syringe and Autoinjector presentations of FYB202
2025-522422-13-00Chronic inflammatory diseases
Fresenius Kabi SwissBioSim GmbH
Immune System Diseases
Poland
03/11/2025
Phase I
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants
2025-522345-21-00Moderately to severely active Crohn’s disease, Moderately t…
Chong Kun Dang Pharmaceutical Corp.
Immune System Diseases
Poland
26/10/2025
Phase I
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)
2025-521315-39-00Axial spondyloarthritis
Grey Wolf Therapeutics Limited
Hemic and Lymphatic Diseases
Belgium, Germany, Netherlands, Spain, Poland
06/10/2025
Phase I
A first-in-human, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.
2025-521658-40-00Atopic dermatitis
Egle Therapeutics
Skin and Connective Tissue Diseases
Germany, Bulgaria, Poland
01/10/2025
Phase I
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2024-514152-32-00Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CL…
F. Hoffmann-La Roche AG
Neoplasms
France, Spain, Poland
25/09/2025
Phase I
A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A
2025-520490-38-00Haemophilia A with or without inhibitors. Proposed indicati…
Novo Nordisk A/S
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Poland, Spain, Austria, Italy, Germany, Belgium, France, Portugal, Sweden
22/09/2025
Rows per page Showing 26–39 of 39
Previous 1 2
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-europe/country/poland

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.